PDCD1 and renal cell adenocarcinoma: Fifthly, the addition of anti-PD1/PDL1 antibodies to radical treatment has improved the prognosis of non-metastatic NSCLC, melanoma, renal cell cancer, bladder cancer, and triple-negative breast cancer.